

PRESS RELEASE

OncoDNA and MD Anderson Cancer Center Madrid sign important collaboration agreement

- MD Anderson Madrid will have access to OncoDNA's entire portfolio of products
- Collaboration will enhance the use of precision medicine tools at leading cancer centre

Gosselies, Belgium – June 06, 2018:

OncoDNA ("OncoDNA or "the Company"), the healthcare technology company making precision medicine a reality, is pleased to announce that it has signed a collaboration agreement with MD Anderson Cancer Center Madrid, an affiliate of the MD Anderson Cancer Center in Houston, Texas, one of the most prestigious diagnostic, treatment and oncology research centres in the world.

The agreement was signed by Nuria González, general director of MD Anderson Madrid, and Adriana Terrádez, sales director of OncoDNA for Spain and Portugal, at the Madrid headquarters of the cancer centre. Through this alliance, the oncologists who work there will be able to use the entire portfolio of genomic analyses offered by OncoDNA for patients who meet the necessary criteria.

«Through this agreement we have expanded our catalogue of tools for personalised diagnosis and monitoring of our patients. Using OncoDNA's tests makes it easier to find a successful treatment and improve the prospects of success in the face of the disease,» said Enrique Grande, head of the Medical Oncology services at MD Anderson Madrid. «These tests are a key element in precision oncology, and with them we can find a target treatment for each person and avoid unnecessary side effects generated by incorrect therapies.»

Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, commented: *«We have entered an agreement with one of the most prestigious cancer centres in the world and we hope to continue our collaboration for many years. We will be carrying out genomic studies, but also we will be conducting research in order to achieve more effective and less invasive methods in the fight against cancer.»*

This significant collaboration follows a series of agreements signed with several Spanish hospitals and clinics in recent months. It demonstrates the increasing interest in applying precision medicine approaches to improving clinical care in oncology.

ABOUT ONCODNA :

OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database called OncoKDO™ that continuously 'learns' from cutting-edge, validated, scientific and medical advances. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to an individual patient's cancer profile. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, and employs c. 55 employees in four countries.

For further information, visit www.oncodna.com

ABOUT MD ANDERSON CANCER CENTER MADRID :

MD Anderson Cancer Center Madrid is an affiliate of the prestigious MD Anderson Cancer Center in Houston, Texas, USA. With more than eighteen years' history in Spain, MD Anderson Cancer Center Madrid currently offers modern facilities with over 150 medical specialists trained in oncology, a total of 87 hospitalization beds and state-of-the-art technology for the diagnosis and treatment of the different types of cancer.

This large infrastructure, together with continuous, close collaboration with the MD Anderson center in Houston on investigation, like protocols for diagnosis and treatment with the participation of a multidisciplinary team of specialists, make MD Anderson Cancer Center Madrid one of the leading hospitals in Europe in cancer treatment.

For further information, visit www.mdanderson.es

CONTACT

OncoDNA :

Jean-Pol Detiffe, CEO
Pierre Flamant, CFO

+32 (0) 71 18 35 00

Consilium Strategic Communications :

Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thys

+44 (0)20 3709 5700

oncodna@consilium-comms.com

